OUR TEAM

Randy Schreckhise

CEO & Co-founder
Randy has made contributions to a number of approved therapeutics and therapeutic candidates through finance, business development, operations and strategy roles at aTyr Pharma, Abilita Bio, Trius Therapeutics, Ardea Biosciences, Human Genome Sciences and ZymoGenetics, and also through work in project management, protein biochemistry and genetics during his eight years at ZymoGenetics. Earlier in his career he worked in the Basic Sciences and Clinical Divisions at The Fred Hutchinson Cancer Research Center, where he studied meiotic recombination of the fission yeast S. pombe and also developed DNA-based assays for the detection of invasive fungal disease. For the past six years, Randy has been an active member of The San Diego Entrepreneurs Exchange, and currently serves as President and Board Member. He received an MBA with a concentration in finance from Seattle University and a BS in microbiology with a minor in molecular biology from Washington State University, where he was a Howard Hughes Undergraduate Research Fellow.
Mark

Mark Sullivan, MD, MPH

Co-founder
Dr. Mark Sullivan holds undergraduate degrees in microbiology and molecular biology through Washington State University and advanced degrees of Doctor of Medicine and Master of Public Health both through the University of Washington. He is a board certified physician in three specialties of Internal Medicine, Critical Care Medicine, and Occupational/Environmental Medicine with special interest in toxic exposure assessment and treatment. Dr. Sullivan completed his MPH research thesis on the association between transition metal components of < 2.5 micron particulate matter (PM 2.5) and lung function and density as potentially relates to chronic obstructive pulmonary disease (COPD) prevalence. Past research experience includes identifying the structure of the working genome of the Human Foamy Retrovirus at Fred Hutchinson Cancer Research Center, and helping to identify the Alzheimer’s and Werner’s disease gene locus at the University of Washington.
Dave

David Giegel, PhD

Chief Scientific Officer & SAB Chair
Dr. Giegel brings more than twenty-five years of expertise in drug discovery and development to August Therapeutics. He most recently served as President and Chief Scientific Officer of TissueNetix, Inc., a company he founded. Prior to TissueNetix, Dr. Giegel was President and Chief Scientific Officer of MicroStem. Previously, he was an Adjunct Associate Research Professor at San Diego State University, and was Entrepreneur-in-Residence at CONNECT, San Diego, where he mentored companies in the Springboard Program. Dr. Giegel also was Senior Director of the Molecular Sciences Group at Celgene, and held scientific leadership positions at MitoKor, Pfizer, and Warner-Lambert/Parke-Davis. He earned his Ph.D. in Biological Chemistry from the University of Michigan and a B.S. in Chemistry from Miami University in Ohio.
AMy

Amy Arthur, PhD

Consultant
Amy is an R&D Program and Alliance Management professional with over 17 years of successful, collaborative leadership and management, supporting the biotechnology and pharmaceutical industries from early research through lead optimization to development candidates. Her educational and research background encompassed chemistry, pharmacology and toxicology at Goucher College (bachelor’s degree), Dartmouth College (doctorate), the National Cancer Institute at the National Institutes of Health (postdoctoral fellowship), and a Research Professor in the Departments of Chemistry, and Pharmacology and Toxicology at Dartmouth College and Medical School. She began her biotechnology career in San Diego at Digital Gene Technologies, followed by Senomyx, where she established and headed the Program & Alliance Management Department for over 13 years, managing external collaborations with prominent companies in the food and beverage industry, supporting cross-functional research projects discovering small molecules that modulate taste receptors, and leading the development of flavor ingredients through pre-clinical toxicology, manufacturing, and regulatory submissions, which resulted in approval of 14 flavor ingredients at various stages of commercialization. She furthered her knowledge of research project management at Vertex Pharmaceuticals and is currently honing her business skills in Business Development at the global CRO Pharmaron, where she focuses on building strong client relationships and specializes in chaperoning startups through discovery biology, chemistry, CMC and  IND enabling studies.  She has 26 published manuscripts in peer reviewed journals and 2 published patents; was PI or Co-PI on 5 research grants; and received 10 awards for excellence in research and teaching.
Menu